[go: up one dir, main page]

PE20010127A1 - Suspension de ziprasidona - Google Patents

Suspension de ziprasidona

Info

Publication number
PE20010127A1
PE20010127A1 PE2000000480A PE0004802000A PE20010127A1 PE 20010127 A1 PE20010127 A1 PE 20010127A1 PE 2000000480 A PE2000000480 A PE 2000000480A PE 0004802000 A PE0004802000 A PE 0004802000A PE 20010127 A1 PE20010127 A1 PE 20010127A1
Authority
PE
Peru
Prior art keywords
ziprasidone
alkaline metal
metal chlorides
composition
suspension
Prior art date
Application number
PE2000000480A
Other languages
English (en)
Inventor
Daniel Ray Arenson
Hong Qi
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20010127(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010127A1 publication Critical patent/PE20010127A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Dental Preparations (AREA)
  • Cosmetics (AREA)
  • Colloid Chemistry (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE LA BASE LIBRE DE ZIPRASIDONA O UNA SAL DE ADICION DE ACIDOS DE ZIPRASIDONA; AGUA, POLISORBATO 20, 21, 40, 60, 61, 65, 80, 81, 85, 120; UN AGENTE DE VISCOSIDAD, DIOXIDO DE SILICIO COLOIDAL, UN AGENTE ENMASCARANTE DEL SABOR COMO CLORUROS DE METALES ALCALINOS, CLORUROS DE METALES ALCALINO TERREOS. LA COMPOSICION ES DE PREFERENCIA UNA SUSPENSION ORAL QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE LA PSICOSIS
PE2000000480A 1999-05-27 2000-05-22 Suspension de ziprasidona PE20010127A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13626899P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
PE20010127A1 true PE20010127A1 (es) 2001-02-06

Family

ID=22472103

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000480A PE20010127A1 (es) 1999-05-27 2000-05-22 Suspension de ziprasidona

Country Status (50)

Country Link
EP (1) EP1181018B1 (es)
JP (1) JP3942827B2 (es)
KR (1) KR100477782B1 (es)
CN (1) CN1196486C (es)
AP (1) AP1409A (es)
AR (1) AR022643A1 (es)
AT (1) ATE234097T1 (es)
AU (1) AU777413B2 (es)
BG (1) BG65367B1 (es)
BR (1) BR0010990A (es)
CA (1) CA2371550C (es)
CO (1) CO5170458A1 (es)
CR (1) CR6506A (es)
CU (1) CU23223B7 (es)
CZ (1) CZ20014230A3 (es)
DE (1) DE60001649T2 (es)
DK (1) DK1181018T3 (es)
DZ (1) DZ3049A1 (es)
EA (1) EA003907B1 (es)
EE (1) EE04704B1 (es)
ES (1) ES2191618T3 (es)
GC (1) GC0000190A (es)
GE (1) GEP20033113B (es)
GT (1) GT200000081A (es)
HK (1) HK1046366B (es)
HN (1) HN2000000071A (es)
HR (1) HRP20010878B1 (es)
HU (1) HUP0201297A3 (es)
IL (2) IL145950A0 (es)
IS (1) IS2396B (es)
MA (1) MA26741A1 (es)
MX (1) MXPA01012124A (es)
MY (1) MY127891A (es)
NO (1) NO320296B1 (es)
NZ (1) NZ514764A (es)
OA (1) OA11946A (es)
PA (1) PA8495801A1 (es)
PE (1) PE20010127A1 (es)
PL (1) PL196867B1 (es)
RS (1) RS50089B (es)
SI (1) SI1181018T1 (es)
SK (1) SK284590B6 (es)
SV (1) SV2001000085A (es)
TN (1) TNSN00112A1 (es)
TR (1) TR200103392T2 (es)
TW (1) TWI263498B (es)
UA (1) UA59491C2 (es)
UY (1) UY26166A1 (es)
WO (1) WO2000072847A1 (es)
ZA (1) ZA200109692B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
KR101197919B1 (ko) 1999-10-29 2012-11-29 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
BR0308343A (pt) * 2002-03-12 2006-06-06 Bristol Myers Squibb Co composições farmacêuticas na forma de pó, método para preparar uma suspensão oral de uma droga, método para mascarar o sabor amargo ou outro sabor de uma droga e suspensão oral de des-quinolona
CN1703198A (zh) * 2002-10-25 2005-11-30 辉瑞产品公司 呈混悬剂形式的芳基杂环活性物质的贮库制剂
JP2006514923A (ja) * 2002-10-25 2006-05-18 ファイザー・プロダクツ・インク 注射可能な新規なデポ製剤
MXPA03009945A (es) 2002-11-05 2007-04-16 Lg Electronics Inc Montaje para montar una pantalla de toque para un monitor con pantalla de cristal liquido.
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
EP1744750A2 (en) 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
BRPI0612297A2 (pt) * 2005-06-20 2010-11-03 Elan Pharma Int Ltd composição de nanoparticulado estável, método para prepará-la, uso da mesma, composição farmacêutica, uso da mesma, forma de dosagem, composição de liberação controlada, e, uso da mesma
WO2007052289A2 (en) 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
JP4336380B1 (ja) * 2008-11-06 2009-09-30 塩野義製薬株式会社 水懸濁性を向上させた細粒剤
JP6272730B2 (ja) * 2014-05-21 2018-01-31 救急薬品工業株式会社 速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
AR022643A1 (es) 2002-09-04
TNSN00112A1 (fr) 2005-11-10
TR200103392T2 (tr) 2002-11-21
IL145950A0 (en) 2002-07-25
GT200000081A (es) 2001-11-16
HRP20010878B1 (en) 2007-03-31
DE60001649T2 (de) 2003-08-21
AU4138500A (en) 2000-12-18
IS6134A (is) 2001-10-30
IS2396B (is) 2008-08-15
HN2000000071A (es) 2001-02-02
EE200100633A (et) 2003-02-17
CN1196486C (zh) 2005-04-13
PL352826A1 (en) 2003-09-08
EP1181018A1 (en) 2002-02-27
GC0000190A (en) 2006-03-29
PL196867B1 (pl) 2008-02-29
KR20020048307A (ko) 2002-06-22
YU76701A (sh) 2005-07-19
NZ514764A (en) 2004-04-30
ES2191618T3 (es) 2003-09-16
BR0010990A (pt) 2002-03-05
EE04704B1 (et) 2006-10-16
CR6506A (es) 2004-03-24
WO2000072847A1 (en) 2000-12-07
DK1181018T3 (da) 2003-04-22
ATE234097T1 (de) 2003-03-15
HUP0201297A3 (en) 2005-09-28
AP2001002346A0 (en) 2001-12-31
NO320296B1 (no) 2005-11-21
AU777413B2 (en) 2004-10-14
DZ3049A1 (fr) 2004-03-27
EA003907B1 (ru) 2003-10-30
EP1181018B1 (en) 2003-03-12
AP1409A (en) 2005-06-13
IL145950A (en) 2007-12-03
CN1352560A (zh) 2002-06-05
GEP20033113B (en) 2003-11-25
JP3942827B2 (ja) 2007-07-11
CO5170458A1 (es) 2002-06-27
EA200101131A1 (ru) 2002-04-25
NO20015755L (no) 2002-01-23
NO20015755D0 (no) 2001-11-26
JP2003500449A (ja) 2003-01-07
TWI263498B (en) 2006-10-11
UA59491C2 (uk) 2003-09-15
HRP20010878A2 (en) 2003-06-30
BG106153A (bg) 2002-06-28
MY127891A (en) 2006-12-29
HK1046366A1 (en) 2003-01-10
SV2001000085A (es) 2001-11-08
CU23223B7 (es) 2007-08-30
KR100477782B1 (ko) 2005-03-21
SI1181018T1 (en) 2003-06-30
CA2371550C (en) 2007-01-02
CA2371550A1 (en) 2000-12-07
PA8495801A1 (es) 2001-12-14
RS50089B (sr) 2009-01-22
MXPA01012124A (es) 2002-06-04
SK284590B6 (sk) 2005-07-01
MA26741A1 (fr) 2004-12-20
CZ20014230A3 (cs) 2002-08-14
BG65367B1 (bg) 2008-04-30
ZA200109692B (en) 2002-11-26
UY26166A1 (es) 2000-12-29
DE60001649D1 (de) 2003-04-17
HK1046366B (zh) 2005-07-29
OA11946A (en) 2006-04-13
SK16782001A3 (sk) 2002-09-10
HUP0201297A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
PE20010127A1 (es) Suspension de ziprasidona
CO5700797A2 (es) Composicion de farmaco conjugado
BG106681A (en) Solutions containing epinastine
ES2061890T3 (es) Soluciones acuosas estabilizadas de 3-isotiazolinonas.
DE69316170D1 (de) Orale Formulierung zum verbesserten Bleichen von Zähnen
AU3701100A (en) Deodorant compositions containing cyclodextrin odor controlling agents
AR024874A1 (es) Composiciones bactericidas
HRP20020198B1 (hr) Formulacija moksifloksacina i kuhinjske soli
PE44595A1 (es) Enjuague bucal concentrado para un suministro eficiente de agentes antimicrobianos
BG106602A (en) Formulation of substituted benzimidazoles
BR9903257A (pt) Concentrado de suspensão aquosa contendo tiadiazurona e etefona
BR0008445A (pt) Emulsões pit
BG103306A (en) Liquid allendronate compositions
BR0115026A (pt) Composição agroquìmica
DE60219462D1 (de) Verdickte wässrige zusammensetzungen
WO2004000372A3 (de) Desinfizierende zusammensetzung, daraus hergestellte reinigungstablette und deren verwendung
DE60208210D1 (de) Konzentriertes kapsulemittel für detergenz- oder körperpflegezusammensetzungen
NO994692D0 (no) Emulgert geleringsmiddel
PE47099A1 (es) Compuestos de 2-imidazolinilaminoindazol utiles como agonistas de alfa-2 adrenoreceptores
WO2003051297A3 (en) Aqueous ifosfamide composition
FR2802101B1 (fr) Association de cymemazine et d'un neuroleptique atypique
AR040600A1 (es) Composicion farmaceutica estable que comprende eritropoietina
ES2149736T1 (es) Composiciones farmaceuticas conteniendo derivados de tienopiridina estables y libres de antioxidantes.
ATE447961T1 (de) Flüssigkeit für herzstillstand
CO4130312A1 (es) Composiciones blanqueadoras perfumadas de hipoclorito

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed